Floatz logo

Zimberelimab

Hepatobiliary Cancer

University of Texas Southwestern Medical Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hepatobiliary Cancer cohort.

Asset / SponsorPhaseRating
Domvanalimab
University of Texas Southwestern Medical Center
Phase 2CCC
Nivolumab
Forma Therapeutics, Inc.
Phase 1/2CCC
Azacitidine
Forma Therapeutics, Inc.
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Forma Therapeutics, Inc.
Phase 1/2CCC
Olutasidenib
Forma Therapeutics, Inc.
Phase 1/2CCC

View all 9 →

Same molecule, other indications

Zimberelimab is also rated in:

Androgen-Resistant Prostatic NeoplasmsDormant
B
Indicative ·
60 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →